Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.
about
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.Diets based on virgin olive oil or fish oil but not on sunflower oil prevent age-related alveolar bone resorption by mitochondrial-related mechanisms.Relationship between Biochemical Bone Markers and Bone Mineral Density in Patients with Phenylketonuria under Restricted Diet.MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.Role of Regulators of G Protein Signaling Proteins in Bone Physiology and Pathophysiology.Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding AffinityScreening of osteoprotegerin-related feature genes in osteoporosis and functional analysis with DNA microarray.Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.Prediction of hip osteoporotic fractures from composite indices of femoral neck strength.Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.Coenzyme Q Protects Against Age-Related Alveolar Bone Loss Associated to n-6 Polyunsaturated Fatty Acid Rich-Diets by Modulating Mitochondrial Mechanisms.Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation.The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.IL-20 bone diseases involvement and therapeutic target potential.
P2860
Q34440107-818CB870-E9B5-4AC3-B356-7C5E83657F38Q34997287-6A28A740-AD1D-4971-84C9-EAF1B0FA68C0Q35177301-8FA0A4D1-ED5A-45F0-A94E-42AF865BBAC1Q36326306-89BA7597-21A3-422B-ABF3-59E3F45736A8Q36756644-8CA12A6B-184C-4266-85D8-0483BCA3B668Q36835372-AB5E17B3-4436-4BA8-8F26-007D5841FF59Q37075242-0020B816-7FD5-4CA4-9D39-14E3535FC19EQ37396629-B66ADF25-9013-4D39-A3FD-BF860DD35120Q38331262-1E3F8F71-215E-4311-BCEE-AC7134A0F122Q40464930-A113FB36-1E0A-498B-ADA7-56F1478CC897Q44815139-52FA28A2-32E8-4678-BD6C-A22F36780C0EQ47400369-90072017-21E0-4C8B-B4D8-8484A6FE1B7BQ51608997-9B1AB690-6452-489D-9F8B-6036970E01A7Q51760981-C4946F31-4FE9-4C18-AE1D-EE3301F4B05BQ53765744-2455A2B9-230B-45B2-B946-3080195DB836Q55121772-4CB08BED-EA7B-4B4A-BE5C-0943E1D60679
P2860
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Selective targeting of RANK si ...... c strategies for osteoporosis.
@ast
Selective targeting of RANK si ...... c strategies for osteoporosis.
@en
Selective targeting of RANK si ...... c strategies for osteoporosis.
@nl
type
label
Selective targeting of RANK si ...... c strategies for osteoporosis.
@ast
Selective targeting of RANK si ...... c strategies for osteoporosis.
@en
Selective targeting of RANK si ...... c strategies for osteoporosis.
@nl
prefLabel
Selective targeting of RANK si ...... c strategies for osteoporosis.
@ast
Selective targeting of RANK si ...... c strategies for osteoporosis.
@en
Selective targeting of RANK si ...... c strategies for osteoporosis.
@nl
P2860
P1476
Selective targeting of RANK si ...... ic strategies for osteoporosis
@en
P2093
P2860
P304
P356
10.1517/14728222.2010.511179
P407
P577
2010-09-01T00:00:00Z